Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Wave Life Sciences headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Therapeutics sector. The company focuses on Biotechnology and has secured $96.0B in funding across 144 round(s). With a team of 251-500 employees, Wave Life Sciences is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Wave Life Sciences, raised $18.0M. Discover more about their projects, partnerships, and impact on our platform.